Carisma Therapeutics announced the appointment of Marella Thorell and David Scadden, M.D., to the Company’s Board of Directors, effective June 30, 2024. Additionally, Regina Hodits and Bjorn Odlander have informed the Board of their intention to step down as members effective June 30, 2024, due to other professional commitments.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM:
- Carisma Therapeutics nominates first candidate under collaboration with Moderna
- Carisma Therapeutics granted FDA Fast Track designation for CT-0525
- Carisma Therapeutics management to meet virtually with BTIG
- Carisma Therapeutics Grants Executive Stock Options for Retention
- Carisma Therapeutics: First patient dosed in Phase 1 clinical trial of CT-0525